|
Re: anyone has data on pertuzumab+trastuzumab v.s pert+tras+docetaxol
Perjeta is listed on Roche's pipeline as filing post 2014 for second line MBC. Perjeta is to be filed for early breast cancer in 2016. TDM1 filed as first line MBC 2014.
http://www.roche.com/research_and_de...a_pipeline.htm
I have heard different information on FDA approvals that are expected. I can only guess these will be early approvals or fast track?
__________________
Diagnosed 2007
Stage IIb Invasive Ductal Carcinoma, Pagets, 3 of 15 positive nodes
Traditional Treatment: Mastectomy and Axillary Node Dissection followed by Taxotere, 6 treatments and 1 year of Herceptin, no radiation
Former Chemo Ninja "Takizi Zukuchiri"
Additional treatments:
GP2 vaccine, San Antonio Med Ctr
Prescriptive Exercise for Cancer Patients
ENERGY Study, UCSD La Jolla
Reconstruction: TRAM flap, partial loss, Revision
The content of my posts are meant for informational purposes only. The medical information is intended for general information only and should not be used in any way to diagnose, treat, cure, or prevent disease
Last edited by 'lizbeth; 12-12-2012 at 04:36 PM..
Reason: typo
|